Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.

Clinical lymphoma, myeloma & leukemia - 1 Sept 2014

Pasquier Florence, Cabagnols Xenia, Secardin Lise, Plo Isabelle, Vainchenker William

Abstract excerpt

The discovery of the JAK2V617F mutation followed by the discovery of other genetic abnormalities allowed important progress in the understanding of the pathogenesis and management of myeloproliferative neoplasms (MPN)s. Classical Breakpoint cluster region-Abelson (BCR-ABL)-negative neoplasms include 3 main disorders: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). Genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Molecular Targeted Therapy

Share to Mutation

Share to Myeloproliferative Disorders

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Identifiers

PMID: 25486952
DOI: 10.1016/j.clml.2014.06.014

Genes

JAK2
MPL
BCR
CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.PMID 25486952Read ↗

A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative NeoplasmsSemantic proximity Read ↗

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read ↗

Myeloproliferative Neoplasms: A Contemporary Review.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overviewSemantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.